AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1331830 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (both doses)
Number of subjects: 125
Study 4028771 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dressing changes every 24 hours
Number of subjects: 268
Study 4028771 — intervention group
Group type: COMPARATOR
Intervention: Dressing changes every 72 hours
Number of subjects: 268
Study 30929642 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 101
Study 30929642 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 101
Study 29917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 666
Study 29917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 666
Study 29917070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 666
Study 29917070 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (both doses)
Number of subjects: 666
Study 26028408 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture corrective exercise programme in addition to Physical Education classes; duration: 32 weeks
Number of subjects: 130
Study 26028408 — intervention group
Group type: COMPARATOR
Intervention: Physical Education classes only; n = 46
Number of subjects: 130
Study 26028408 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture corrective exercise programme; n = 42
Number of subjects: 130
Study 24810870 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram treatment
Number of subjects: 36
Study 24810870 — intervention group
Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 36
Study 22549241 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Symphytum herb extract cream (Traumaplant®)
Number of subjects: 108
Study 20430934 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 12 weeks
Number of subjects: 37
Study 20430934 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (control)
Number of subjects: 37
Study 18557690 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused group therapy
Number of subjects: 420
Study 18557690 — intervention group
Group type: EXPERIMENTAL
Intervention: Present-centered group therapy
Number of subjects: 420
Study 18557690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing theory
Number of subjects: 420
Study 18557690 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 420
Study 18557690 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP 420 (Trauma-focused vs Present-centered)
Number of subjects: 420
Study 18557690 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP 420 (Clinically significant change categorization)
Number of subjects: 420
Study 15872036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexelizumab 24 h infusion
Number of subjects: 337
Study 15872036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 11967034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC)
Number of subjects: 2534
Study 11967034 — intervention group
Group type: COMPARATOR
Intervention: Iron dextran
Number of subjects: 2534
Study 11967034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bacteriostatic saline)
Number of subjects: 2534
Study 10697623 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (C) alone
Number of subjects: 14
Study 10697623 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (C) and Paclitaxel (P)
Number of subjects: 14
Study 7729281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 4 g/day
Number of subjects: 310
Study 7729281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 1 g/day
Number of subjects: 310
Study 7729281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 2 g/day
Number of subjects: 310
Study 7729281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 2209837 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide (a gastrin receptor antagonist)
Number of subjects: 41
Study 2209837 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 41
Study 6452833 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized fenoterol
Number of subjects: 18
Study 6452833 — intervention group
Group type: COMPARATOR
Intervention: Nebulized disodium cromoglycate (DSCG)
Number of subjects: 18
Study 6452833 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (IPTB)
Number of subjects: 18
Study 6452833 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DSCG and IPTB
Number of subjects: 18
Study 6452833 — intervention group
Group type: COMPARATOR
Intervention: Pulverized tablets of salbutamol, theophylline, and their combination
Number of subjects: 18
Study 31415780 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment for stress urinary incontinence
Number of subjects: 106
Study 28262140 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback with medication (NF condition)
Number of subjects: 36
Study 28262140 — intervention group
Group type: COMPARATOR
Intervention: Medication only condition (Control)
Number of subjects: 36
Study 26468123 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate (200 or 400 μg/d)
Number of subjects: 0
Study 26468123 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine (200 μg/d)
Number of subjects: 0
Study 26468123 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate (400 μg/d)
Number of subjects: 0
Study 26468123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23926583 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-activated disinfection (LAD) with FotoSan
Number of subjects: 80
Study 23926583 — intervention group
Group type: COMPARATOR
Intervention: Control group (mechanical cleaning alone)
Number of subjects: 80
Study 21877766 — intervention group
Group type: EXPERIMENTAL
Intervention: JP formulation of pitavastatin 2 mg
Number of subjects: 60
Study 21877766 — intervention group
Group type: COMPARATOR
Intervention: EU formulation of pitavastatin 2 mg
Number of subjects: 60
Study 19037684 — intervention group
Group type: EXPERIMENTAL
Intervention: Persian WORC
Number of subjects: 150
Study 17479142 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in stroke units
Number of subjects: 0
Study 17479142 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stroke units (offering both acute medical treatment and rehabilitation)
Number of subjects: 0
Study 15176282 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable pull-ups
Number of subjects: 0
Study 15176282 — intervention group
Group type: COMPARATOR
Intervention: Disposable nappies
Number of subjects: 0
Study 11809093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen enrichment to 24% at 3800 m
Number of subjects: 12
Study 11809093 — intervention group
Group type: COMPARATOR
Intervention: Ambient air conditions
Number of subjects: 12
Study 9710685 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin (20-40 mg)
Number of subjects: 220
Study 9710685 — intervention group
Group type: EXPERIMENTAL
Intervention: vitamin E
Number of subjects: 220
Study 9710685 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin + vitamin E
Number of subjects: 220
Study 9710685 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 220
Study 7991936 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus glipizide (3 x 10 mg/day)
Number of subjects: 10
Study 7991936 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 10
Study 2499150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg)
Number of subjects: 0
Study 2499150 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (500 mg)
Number of subjects: 0
Study 2499150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31188707 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP) with behavior change support
Number of subjects: 124
Study 31188707 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP) without behavior change support
Number of subjects: 124
Study 31188707 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 29354987 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture regulating qi based on the compatibility of the five meridians, 30 min sessions, three times a week for 8 weeks.
Number of subjects: 57
Study 29354987 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole orally, for 8 weeks.
Number of subjects: 57
Study 25326831 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippia citriodora extract-PLX(®)
Number of subjects: 33
Study 25326831 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond beverage
Number of subjects: 33
Study 25326831 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both supplements (PLX(®) and almond beverage)
Number of subjects: 33
Study 25326831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 23281041 — intervention group
Group type: EXPERIMENTAL
Intervention: Add teriparatide 20 µg/day
Number of subjects: 168
Study 23281041 — intervention group
Group type: COMPARATOR
Intervention: Switch to teriparatide 20 µg/day
Number of subjects: 168
Study 21079762 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA formulated with Alhydrogel® (50 µg)
Number of subjects: 73
Study 21079762 — intervention group
Group type: EXPERIMENTAL
Intervention: rPA formulated with Alhydrogel® (25 µg)
Number of subjects: 73
Study 21079762 — intervention group
Group type: COMPARATOR
Intervention: Buffered saline placebo
Number of subjects: 73
Study 18431541 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (hot pack, ultrasound therapy, exercise program)
Number of subjects: 42
Study 18431541 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction therapy in addition to standard physical therapy
Number of subjects: 42
Study 16842389 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rac-albuterol
Number of subjects: 14
Study 16842389 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg rac-albuterol
Number of subjects: 14
Study 12805340 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrier oil only
Number of subjects: 313
Study 12805340 — intervention group
Group type: COMPARATOR
Intervention: Carrier oil with fractionated oils
Number of subjects: 313
Study 12805340 — intervention group
Group type: COMPARATOR
Intervention: Pure essential oils of lavender, bergamot, and cedarwood
Number of subjects: 313
Study 11228951 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic treadmill exercise (AEX) for 3 months, 3 times/week
Number of subjects: 5
Study 8899259 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 600
Study 8899259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofem
Number of subjects: 600
Study 1666179 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 427 (ebiratide), administered intravenously in a pulsatile mode 4 times (120 micrograms each) at 2200, 2300, 2400 and 0100
Number of subjects: 0
Study 1666179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7066127 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.1 or 0.2 mg i.v. on patient demand using the 'Cardiff' palliator
Number of subjects: 51
Study 30759283 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐s 2% chlorhexidine digluconate (CHX) application
Number of subjects: 105
Study 30759283 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐s ozone application
Number of subjects: 105
Study 30759283 — intervention group
Group type: COMPARATOR
Intervention: No disinfectant (control)
Number of subjects: 105
Study 28366114 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD) by peer support specialists
Number of subjects: 145
Study 28366114 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD) by nonpeer clinicians
Number of subjects: 145
Study 28366114 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD) with peer support specialists or nonpeer clinicians
Number of subjects: 145
Study 28366114 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated psychiatric advance directive (FPAD)
Number of subjects: 145
Study 25269512 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine-assisted psychotherapy (EAP)
Number of subjects: 90
Study 25269512 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-assisted psychotherapy (CAP)
Number of subjects: 90
Study 25269512 — intervention group
Group type: COMPARATOR
Intervention: Enhanced social skills psychotherapy
Number of subjects: 90
Study 25269512 — intervention group
Group type: COMPARATOR
Intervention: Regular hospital care
Number of subjects: 90
Study 25269512 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 clinical observation
Number of subjects: 90
Study 23816513 — intervention group
Group type: EXPERIMENTAL
Intervention: ALB×1
Number of subjects: 385
Study 23816513 — intervention group
Group type: EXPERIMENTAL
Intervention: MBZ×1
Number of subjects: 385
Study 23816513 — intervention group
Group type: EXPERIMENTAL
Intervention: ALB×2
Number of subjects: 385
Study 23816513 — intervention group
Group type: EXPERIMENTAL
Intervention: MBZ×2
Number of subjects: 385
Study 21078941 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine treatment
Number of subjects: 66
Study 21078941 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro quinine sensitivity testing
Number of subjects: 66
Study 19278356 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude hypoxia (14% O2)
Number of subjects: 6
Study 19278356 — intervention group
Group type: COMPARATOR
Intervention: Room air (21% O2)
Number of subjects: 6
Study 17431728 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 10) - 10-day course including thermal pool baths at 37 degrees C for 20 min two times daily
Number of subjects: 20
Study 17431728 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy (n = 10)
Number of subjects: 20
Study 17431728 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (n = 10) - NSAIDs and paracetamol
Number of subjects: 20
Study 14963281 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg/d
Number of subjects: 83
Study 14963281 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 500 mg/d
Number of subjects: 83
Study 14963281 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin dose reduction from 1300 to 325 or 81 mg/d
Number of subjects: 83
Study 11164206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute metabolic alkalosis (NaHCO(3))
Number of subjects: 15
Study 11164206 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute metabolic acidosis (NH(4)Cl)
Number of subjects: 15
Study 11164206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 15
Study 9393518 — intervention group
Group type: EXPERIMENTAL
Intervention: True-block group (30 mL 0.5% bupivacaine)
Number of subjects: 34
Study 9393518 — intervention group
Group type: COMPARATOR
Intervention: Placebo-block group
Number of subjects: 34
Study 7965420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartrazine (1, 2, 5, 10, 20, 50 mg) administered randomly each morning for 21 days
Number of subjects: 200
Study 7965420 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered randomly each morning for 21 days
Number of subjects: 200
Study 3298594 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 82
Study 3298594 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 82
Study 30353607 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel applicator
Number of subjects: 151
Study 30353607 — intervention group
Group type: COMPARATOR
Intervention: Fletcher group
Number of subjects: 151
Study 30353607 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel group
Number of subjects: 151
Study 26383044 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-oriented coping under high disease controllability
Number of subjects: 92
Study 26383044 — intervention group
Group type: COMPARATOR
Intervention: Avoidance-oriented coping under high disease controllability
Number of subjects: 92
Study 26383044 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-oriented coping under low disease controllability
Number of subjects: 92
Study 26383044 — intervention group
Group type: COMPARATOR
Intervention: Avoidance-oriented coping under low disease controllability
Number of subjects: 92
Study 26383044 — intervention group
Group type: COMPARATOR
Intervention: Experimental conditions (approach vs avoidance)
Number of subjects: 92
Study 25007362 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole nitrate foam 1%
Number of subjects: 495
Study 25007362 — intervention group
Group type: COMPARATOR
Intervention: Foam vehicle
Number of subjects: 495
Study 22405255 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 μg vaginally, 2 tablets, 3 hours before abortion)
Number of subjects: 4972
Study 22405255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets, 3 hours before abortion)
Number of subjects: 4972
Study 22405255 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 4972
Study 22405255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4972
Study 20173276 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video (Syphilis and Men)
Number of subjects: 206
Study 20173276 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 206
Study 17710126 — intervention group
Group type: EXPERIMENTAL
Intervention: Four‐Agents‐Decoction (Si Wu Tang)
Number of subjects: 78
Study 17710126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 15552635 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of 1000 mg extended-release divalproex sodium
Number of subjects: 100
Study 15552635 — intervention group
Group type: COMPARATOR
Intervention: Evening dosing of 1000 mg extended-release divalproex sodium
Number of subjects: 100
Study 11518478 — intervention group
Group type: EXPERIMENTAL
Intervention: Li 1370 (240 mg)
Number of subjects: 10
Study 11518478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom only
Number of subjects: 0
Study 10097485 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom plus school-as-community
Number of subjects: 0
Study 10097485 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 8159022 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic cardiopulmonary bypass (37 degrees C)
Number of subjects: 52
Study 8159022 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic cardiopulmonary bypass (27 degrees C)
Number of subjects: 52
Study 3414595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diets
Number of subjects: 0
Study 3414595 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fatty acid chain length and saturation
Number of subjects: 0
Study 3414595 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary cholesterol levels
Number of subjects: 0
Study 29366988 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7652 (PCSK9 inhibiting antibody)
Number of subjects: 0
Study 26865332 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Fr catheter
Number of subjects: 254
Study 26865332 — intervention group
Group type: COMPARATOR
Intervention: 5-Fr catheter
Number of subjects: 254
Study 24438596 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (0.2%) application
Number of subjects: 45
Study 24438596 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 45
Study 23381064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician plus nurse observation during withdrawal
Number of subjects: 502
Study 23381064 — intervention group
Group type: COMPARATOR
Intervention: Routine colonoscopy
Number of subjects: 502
Study 23381064 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse observation
Number of subjects: 502
Study 20490383 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth therapy of periodontitis (nonsurgical treatment) between 22 and 30 weeks of gestation
Number of subjects: 54
Study 20490383 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group 3)
Number of subjects: 54
Study 20490383 — intervention group
Group type: COMPARATOR
Intervention: Declined treatment (group 2)
Number of subjects: 54
Study 18550744 — intervention group
Group type: EXPERIMENTAL
Intervention: GSPBRT‐PCR
Number of subjects: 600
Study 18550744 — intervention group
Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 600
Study 16898856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine effervescent tablets (Zantac EFFERdose)
Number of subjects: 102
Study 16898856 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine syrup (Zantac)
Number of subjects: 102
Study 16898856 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 102
Study 14980948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microg/kg dexmedetomidine
Number of subjects: 30
Study 14980948 — intervention group
Group type: COMPARATOR
Intervention: 0.5% lidocaine + 1 mL isotonic saline
Number of subjects: 30
Study 11601114 — intervention group
Group type: EXPERIMENTAL
Intervention: Various types of osteosyntheses including sliding hip screw, neck screws, intramedullary nails with neck screw, retrograde intramedullary nails, external fixation, cannulated screws, various plates, tension band wiring, threaded K-pins, and arthroplasties.
Number of subjects: 0
Study 11601114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone grafting and substitutes (biologically inert, osteoconductive, or osteoinductive) and osteoinductive growth factors and hormones as supplements to treatment.
Number of subjects: 0
Study 9834259 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional omeprazole, 20 mg at bedtime
Number of subjects: 12
Study 9834259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg at bedtime
Number of subjects: 12
Study 9834259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg at bedtime
Number of subjects: 12